Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy
M A Brantley Jr, S L Edelstein, J M King, M R Plotzke, R S Apte, S M Kymes, A Shiels, M A Brantley Jr, S L Edelstein, J M King, M R Plotzke, R S Apte, S M Kymes, A Shiels
Abstract
Aim: To determine whether there is an association between complement factor H (CFH) or LOC387715 genotypes and response to treatment with photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD).
Methods: Sixty-nine patients being treated for neovascular AMD with PDT were genotyped for the CFH Y402H and LOC387715 A69S polymorphisms by allele-specific digestion of PCR products. AMD phenotypes were characterized by clinical examination, fundus photography, and fluorescein angiography.
Results: Adjusting for age, pre-PDT visual acuity (VA), and lesion type, mean VA after PDT was significantly worse for the CFH TT genotype than for the TC or CC genotypes (P=0.05). Post-PDT VA was significantly worse for the CFH TT genotype in the subgroup of patients with predominantly classic choroidal neovascular lesions (P=0.04), but not for the patients with occult lesions (P=0.22). For the LOC387715 A69S variant, there was no significant difference among the genotypes in response to PDT therapy.
Conclusions: The CFH Y402H variant was associated with a response to PDT treatment in this study. Patients with the CFH TT genotype fared significantly worse with PDT than did those with the CFH TC and CC genotypes, suggesting a potential relationship between CFH genotype and response to PDT.
Conflict of interest statement
No conflicting relationship exists for any author.
Source: PubMed